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Chronic obstructive lung disease (COPD) 
is a major healthcare problem. It is not only an 
important cause of chronic morbidity but also the 
fourth leading cause of mortality worldwide [1]. 
Moreover, due to population aging and exposure 
to risk factors, the global burden of COPD is pro-
jected to further increase in the nearest future [2]. 
Although COPD has been characterized as 
preventable and treatable disease, most experts 
agree that both COPD prevention and treatment 
are challenging. While the number of smokers 
in well developed countries is decreasing, the 
percentage of young people who begin to smoke 
is still alarmingly high in many poor developing 
countries. The management of COPD should be 
based on multidirectional approach, that includes 
lifestyle changes (smoking cessation), education, 
pharmacotherapy, pulmonary rehabilitation, vac-
cinations, oxygen therapy, and others. It must be 
admitted, however, that the efficacy of pharma-
cological treatment is unsatisfactory. In clinical 
trials that applied lung function as a primary or 
secondary outcome, none of the medications has 
been shown to significantly modify the long term 
decline in lung function [2]. On the other hand, 
the advances in COPD management that were 
made in last decades should also be emphasized 
and appreciated. One of the most important chang-
es in the approach to COPD studies was the ap-
plication of the new outcome measures in clinical 
trials evaluating the efficacy of different therapies. 
The need for redefining of the outcome measures 
has become evident in the first years of the 21st 
century. Until that time, the only outcome that 
was recognized by different international agencies 
evaluating medical products was improvement in 
lung function, particularly in the forced expiratory 
volume in 1 second (FEV1). However, it has been 
realized that the use of such a specific outcome 
which in fact reflects only a  single biological 
variable could result in missing other potential 
beneficial effects of therapeutic interventions 
[3]. Therefore, numerous new outcome measures 
have been widely applied in further studies as-
sessing the efficacy of COPD management. These 
include: dyspnea score, health status, frequency 
and severity of exacerbations, exercise capacity, 
quality of life (QOL), cognitive function, the 
multi-dimensional symptom scores, mortality and 
other. The use of these outcomes clearly showed 
that some relevant therapeutic effects can be 
achieved in COPD patients even when there is no 
significant improvement in lung function assessed 
by spirometry. One of the most important tools 
to assess health status in COPD patients is the 
St. George’s Respiratory Questionnaire (SGRQ). 
This questionnaire has been originally designed 
to measure and quantify the health-related quality 
of life in patients with chronic airflow limitation 
[4]. Later, a COPD specific version had also been 
developed [5]. Since then, the SGRQ has been 
widely used in clinical trials to measure the effect 
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of various therapies. Currently, it is regarded as 
a quasi standard in clinical trials [3]. The mini-
mal important difference (MID) in SGRQ score 
has been evaluated by different methods, and 
changes of 2 to 8 points were considered clinically 
significant. A decline in SGRQ score ≥ 4 points 
is generally accepted as the minimal difference 
indicating a significant improvement in quality 
of life [3]. 
In the last two decades, several novel thera-
peutic interventions were developed for patients 
with COPD, particularly for those with predomi-
nating emphysema. These include different bron-
choscopic techniques referred to as bronchoscopic 
lung volume reduction (BLVR) or endoscopic 
lung volume reduction (ELVR). The common de-
nominator for all these methods is the use of the 
fiberoptic bronchoscope to reduce lung hyperin-
flation and improve the distribution of lung ven-
tilation. This can be achieved by endobronchial 
(intrabronchial) valve implantation, placement of 
lung coils or bronchoscopic thermal vapor abla-
tion (BTVA) of emphysematous lung regions [6, 
7]. Studies on endobronchial valves started more 
than ten years ago, that is before the concepts of 
lung coils or BTVA arose [8]. Therefore, till now 
significantly more patients have been treated with 
valves than with lung coils and BTVA. In conse-
quence, more data are available on the efficacy 
and safety of endobronchial valves than on other 
bronchoscopic therapies applied in COPD. In the 
recent meta-analysis by Iftikhar et al. the authors 
were able to identify 8 studies on endobronchial 
valves as compared to two small studies on lung 
coils and only one study on BTVA [9]. It must be 
admitted, however, that there has been growing 
interest in the treatment with lung coils and there 
are some interesting recent results [10] as well 
as ongoing studies on this technique [e.g. Lung 
Volume Reduction Coil Treatment in Patients With 
Emphysema (RENEW) Study, NCT01608490]. 
In this issue of “Polish Pneumonology and Al-
lergology” a paper by Szlubowska et al. presenting 
the effect of treatment with intrabronchial valves 
(IBV) in patients with severe emphysema has been 
published [11]. The authors showed that the mean 
difference between the SGRQ score measured 
before and after three months from treatment was 
–12.8 ± 11.9 points and that in 13/20 patients this 
difference was greater than 4 points. These results 
suggest significant improvement of quality of life 
in 70% of patients treated with IBV. However, 
the true impact of treatment with IBVs on health 
related quality of life should be interpreted with 
caution. This is because in severe COPD the MID 
in SGRQ score may be higher than 4 points. Re-
cently, Welling et al. proposed alternative SGRQ 
MID values for patients with severe COPD treat-
ed with BLVR. These values are –8.3 units at 1 
month and –7.1 units at 6 months follow-up after 
intervention [12]. If those MID values were used 
in the study by Szlubowska et al. the significant 
improvement in quality of life would be found in 
smaller number of patients. The above study also 
has other limitations. These include short-term 
follow up, and lack of criteria defining heteroge-
neous emphysema. Also, comparative analysis of 
responders and non-responders could have added 
some important data. Nevertheless, the paper is 
interesting, particularly for Polish readers as this 
is the first, prospective study on the relationship 
between IBV treatment and health related quality 
of life in our country.
When therapy with bronchial valves is con-
sidered several practical comments might be 
useful for the readers who are unfamiliar with 
BLVR. First, there are two major types of valves: 
Spiration intrabronchial valves and Zephyr en-
dobronchial valves. Although the construction 
of both valves is different, there are neither 
significant differences between the sites of their 
placement in the airways (even though one is re-
ferred as intrabronchial valve and the second as 
endobronchial valve) nor their effectiveness and 
safety. In the study by Szlubowska et al. Spiration 
IBVs were used but the authors did not include 
data on the average number of valves applied per 
patient and the sites of their placement. In earlier 
studies, the median number of valves implant-
ed to one patient ranged from 3 to 6.7 [13–16]. 
Second, based on the results of previous studies 
three major prerequisites for effective treatment 
have been identified. These include: heteroge-
neous emphysema, lack of collateral ventilation 
and successful lobar exclusion [6, 7]. Thus, in all 
COPD patients who are potential candidates for 
bronchial valve treatment the use of appropriate 
diagnostic methods to demonstrate whether the 
first two criteria are met is indispensable. The 
third determinant of good clinical response is 
proper technique of valve placement to produce 
complete lobar exclusion (and in consequence 
— desired reduction of the lobe volume) [17]. 
Third, the long-term effects of valves are large-
ly unknown and this particularly refers to the 
durability of improvement. Most of the studies 
published to date evaluated the effects of treat-
ment after 3, 6 and 12 months. Fourth, there is 
no reimbursement for severe COPD treatment 
with bronchial valves in Poland. The treatment is 
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relatively expensive with the approximate cost of 
one valve 1,000 EUR (4.300 PLN). In view of this 
fact, the authors should be congratulated that they 
were able to perform the study with no external 
financial support. The lack of external funds for 
the study may explain the relatively small study 
group. Regarding the small number of involved 
patients it should also be remembered that, con-
trary to some previous studies that reported larger 
study groups, this was a single center study. 
In summary, BLVR is one of the therapeutic 
option for patients with advanced emphysema. 
This therapy may improve both pulmonary func-
tion and health related quality of life. As BLVR is 
rapidly growing area of knowledge that utilizes 
novel exciting technologies we will certainly hear 
about it again in the near future. 
Conflict of interest
The author declare no conflict of interest.
References:
1. World Health Report. Geneva: World Health Organization. 
Available from URL: http://www.who.int/whr/2000/en/whr00_
en.pdf?ua=1; 2000.
2. Global Strategy for the Diagnosis, Management and Prevention 
of COPD. Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) 2015. Available from: http://www.goldcopd.org/.
3. Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic 
obstructive pulmonary disease (COPD): strengths and limita-
tions. Respir Res 2010; 11: 79. doi: 10.1186/1465-9921-11-79.
4. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-com-
plete measure of health status for chronic airflow limitation. 
The St. George’s Respiratory Questionnaire. Am Rev Respir Dis 
1992; 145: 1321–1327. 
5. Meguro M, Barley EA, Spencer S, Jones PW. Development and 
validation of an improved, COPD-specific version of the St. 
George Respiratory Questionnaire. Chest 2007; 132: 456–463.
6. Gompelmann D, Eberhardt R, Herth F. Endoscopic volume 
reduction in COPD — a critical review. Dtsch Arztebl Int 2014; 
111: 827–833. doi: 10.3238/arztebl.2014.0827.
7. Mineshita M, Slebos DJ. Bronchoscopic interventions for 
chronic obstructive pulmonary disease. Respirology 2014; 19: 
1126–1137. doi: 10.1111/resp.12362.
8. Snell GI, Holsworth L, Borill ZL et al. The potential for bron-
choscopic lung volume reduction using bronchial prostheses: 
a pilot study. Chest 2003; 124: 1073–1080.
9. Iftikhar IH, McGuire FR, Musani AI. Efficacy of bronchoscopic 
lung volume reduction: a meta-analysis. Int J Chron Obstruct 
Pulmon Dis 2014;  9: 481−491. doi http://dx.doi.org/10.2147/
COPD.S69148.
10. Zoumot Z, Kemp SV, Singh S et al. Endobronchial coils for se-
vere emphysema are effective up to 12 months following treat-
ment: medium term and cross-over results from a randomised 
controlled trial. PLoS One 2015; 10: e0122656. doi: 10.1371/ 
journal.pone.0122656.
11. Szlubowska S, Zalewska-Puchała J, Majda A et al. The influ-
ence of a  lung volume reduction with intrabronchial valves 
on the quality of life of patients with heterogeneous emphy-
sema — a prospective study. Pneumonol Alergol Pol 2015; 83: 
418–423. doi: 10.5603/PiAP.2015.0069.
12. Welling JB, Hartman JE, Ten Hacken NH, Klooster K, Slebos DJ. 
The minimal important difference for the St George’s Respira-
tory Questionnaire in patients with severe COPD. Eur Respir J 
2015. doi: 10.1183/13993003.00535-2015.
13. Sterman DH, Mehta AC, Wood DE et al. A  multicenter 
pilot study of a  bronchial valve for the treatment of se-
vere emphysema. Respiration 2010; 79: 222–233. doi: 
10.1159/000259318.
14. Sciurba FC, Ernst A, Herth FJ et al. A  randomized study of 
endobronchial valves for advanced emphysema. N Engl J Med 
2010; 363: 1233–1244. doi: 10.1056/NEJMoa0900928.
15. Wood DE, Nader DA, Springmeyer SC et al. IBV Valve trial: 
a multicenter, randomized, double-blind trial of endobronchial 
therapy for severe emphysema. J Bronchology Interv Pulmonol 
2014; 21: 288–297. doi: 10.1097/LBR.0000000000000110.
16. Davey C, Zoumot Z, Jordan S  et al. Bronchoscopic lung 
volume reduction with endobronchial valves for patients 
with heterogeneous emphysema and intact interlobar fis-
sures (the BeLieVeR-HIFi study): a  randomised controlled 
trial. Lancet 2015; 386: 1066–1073. doi: 10.1016/S0140-
6736(15)60001-0.
17. Eberhardt R, Gompelmann D, Schuhmann M, Heussel CP, 
Herth FJ. Complete unilateral vs partial bilateral endoscopic 
lung volume reduction in patients with bilateral lung emphy-
sema. Chest 2012; 142: 900–908.
